Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin-Linagliptin vs Empagliflozin-Metformin for Weight Loss in T2DM
NCT07247656Phase 4Completed
- Sponsor
- Bahria University
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin, linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Bahria University. Started Dec 2022; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07247656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247656.